The global monoclonal antibodies market was valued at USD 95.5 billion in 2018 and is expected to reach USD 150.8 billion in 2026, growing at a CAGR of 5.8% during the forecast period.
Monoclonal antibodies derived from one type of immune cell, each a clone of a single parent cell. These antibodies are used in the immunotherapy for the treatment of various chronic diseases such as cancer, Multiple sclerosis, cardiovascular diseases and other. The monoclonal antibodies inhibit and target with the exploit of a receptor or chemical that is involved in the development of the disorder that is being treated.
The growth of the monoclonal antibodies market is primarily driven by the increasing prevalence of the various chronic disease such as cancer, CVD and others across the globe. It can offer information about a condition that may support in the treatment planning. For instance, monoclonal estrogen receptors immunocytochemical assay (ER-ICA) and ER enzyme immunoassay (ER-EIA) are used to measure the level of estrogen receptors in breast tumors. For instance, the global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018, as per World Health Organization (WHO). Moreover, technological advance in the immunoassay further provides growth opportunity to the market.
Monoclonal Antibodies Market Segmentation |
|
| By Type | 1. In-vitro |
| 2. In-vivo | |
| By Indication | 1. Cancer |
| 2. Inflammatory Diseases | |
| 3. Autoimmune Diseases | |
| 4. Infectious Diseases | |
| 5. Microbial Diseases | |
| 6. Others | |
| By End-User | 1. Hospitals |
| 2. Research Institutes | |
| 3. Others | |
| By Region | 1. North America (US and Canada) |
| 2. Europe (UK, Germany, France and Rest of Europe) | |
| 3. Asia Pacific (China, Japan, India and Rest of Asia Pacific) | |
| 4. Latin America (Brazil, Mexico and Rest of Latin America) | |
| 5. Middle East & Africa (GCC and Rest of Middle East & Africa) | |
Based on type, the global monoclonal antibodies market has been segmented into in-vitro and in-vivo. The in-vitro segment is projected to have the fastest growth during the forecast period. The market is mainly driven due to availability of various in-vitro methods for antibody generation including time effectiveness, financial feasibility, and extensive production. These methods are used in vitro for the examination of specimens, including blood and tissue donations, derived from the human body, solely or principally for the purpose of providing information.
The in-vitro segment expected to grow at the fastest rate of 8.2% CAGR during the forecast period
Based on indication, the cancer segment is expected to lead during the forecast period
Based on indication, the market has been segmented into cancer, inflammatory diseases, autoimmune diseases, infectious diseases, microbial diseases, and others. The cancer segment is estimated to have the 35% market share among indication due to the high prevalence of cancer across the globe. Moreover, one in every five men and one in six women worldwide develop cancer during their lifetime, and one in eight men and one in 11 women are registered under mortality cases of the disease. Globally, the total number of people who are alive within five years of a cancer diagnosis, called the 5-year prevalence, is estimated to be 43.8 million in 2018. The monoclonal antibody test uses the binding of antibodies to detect and measure certain substances that augmenting the growth of the market.
The hospital segment is projected to have the largest share in the market
Based on end-user the market is segregated into hospitals, research institutes, and others. The hospital segment is estimated to have the largest share among end-user. Hospitals use various assays and antibodies tests for the diagnosis, prognosis, and treatment of various kinds of cancer in patients at the early stage of development. Research institutes are significantly contributing to the growth of the global market. Research institutes work on R&D activities based on monoclonal antibodies to test efficacy and response to the treatment of various chronic diseases such as cancer and others.
North America to dominate the monoclonal antibodies market throughout the forecast period
North America accounted for nearly 41% share of the global monoclonal antibodies market in 2018 and is expected to dominate the market throughout the forecast period followed by Europe and Asia-Pacific. The market is growing due to significant growth in the life science industry and the availability of funding for clinical diagnostics. For instance, as per the National Science Foundation, R&D expenditures in life science by the US colleges and universities totalled $40.9 billion in 2016, of which $21.8 billion are federal expenditure. Asia-Pacific accounted for the highest CAGR of around 8.8% in the global monoclonal antibodies market during the forecast period.
Company Profiles and Competitive Intelligence:
The major players operating in the global monoclonal antibodies market are Novartis International AG, ( Switzerland), Pfizer Inc(US), GlaxoSmithKline plc(UK), Amgen Inc.(US), Merck & Co., Inc.(the US), Daiichi Sankyo, Inc.(Japan) Abbott Laboratories(US), AstraZeneca(UK), Eli Lilly and Company(US), Johnson & Johnson(US) among others.
Ask for free product review call with the author
Share your specific research requirements for a customized report
Request for due diligence and consumer centric studies
Request for study updates, segment specific and country level reports
TABLE OF CONTENT
Chapter 1 Executive Summary
1.1. Market Summary
1.1.1. Global Monoclonal Antibodies Market, 2016-2026, (USD Million)
1.2. Market Snapshot: Global Monoclonal Antibodies Market
1.3. Market Dynamics
1.4. Global Monoclonal Antibodies Market, by Segment, 2018
1.4.1. Global Monoclonal Antibodies Market, by Type, 2018, (USD Million)
1.4.2. Global Monoclonal Antibodies Market, by Indication, 2018, (USD Million)
1.4.3. Global Monoclonal Antibodies Market, by End-User, 2018, (USD Million)
1.4.4. Global Monoclonal Antibodies Market, by Region, 2018 (USD Million)
1.5. Premium Insights
1.5.1. Monoclonal Antibodies Market in Developed Vs. Developing Economies, 2018 vs 2026
1.5.2. Global Monoclonal Antibodies Market: Regional Life Cycle Analysis
Chapter 2 Market Dynamics
2.1. Market Overview
2.2. Market Drivers
2.2.1. Increasing prevalence of chronic disease
2.2.2. Technological advancement
2.2.3. Growing awareness towards choric disease treatment
2.3. Market Restraints
2.3.1. High cost of therapeutic monoclonal antibodies
2.4. Market Opportunities
2.4.1. Robust pipeline product
2.5. Industry Value Chain Analysis
2.6. Pricing Analysis
2.7. Porter’s Five Forces Analysis
Chapter 3 Global Monoclonal Antibodies Market, by Type
3.1. Market Overview, by Type
3.1.1. Global Monoclonal Antibodies Market, by Type, 2016-2026 (USD Million)
3.1.2. Incremental Opportunity, by Type, 2018
3.2. In-Vitro
3.2.1. Global Monoclonal Antibodies Market, by In-Vitro, 2016-2026, (USD Million)
3.3. In-Vivo
3.3.1. Global Monoclonal Antibodies Market, by In-Vivo, 2016-2026, (USD Million)
Chapter 4 Global Monoclonal Antibodies Market, by Indication
4.1. Market Overview, by Indication
4.1.1. Global Monoclonal Antibodies Market, by Indication, 2016-2026 (USD Million)
4.1.2. Incremental Opportunity, by Indication, 2018
4.2. Cancer
4.2.1. Global Monoclonal Antibodies Market, by Cancer, 2016-2026, (USD Million)
4.3. Inflammatory Diseases
4.3.1. Global Monoclonal Antibodies Market, by Inflammatory Diseases, 2016-2026, (USD Million)
4.4. Autoimmune Diseases
4.4.1. Global Monoclonal Antibodies Market, by Autoimmune Diseases, 2016-2026, (USD Million)
4.5. Infectious Diseases
4.5.1. Global Monoclonal Antibodies Market, by Infectious Diseases, 2016-2026, (USD Million)
4.6. Microbial Diseases
4.6.1. Global Monoclonal Antibodies Market, by Microbial Diseases, 2016-2026, (USD Million)
4.7. Others
4.7.1. Global Monoclonal Antibodies Market, by Others, 2016-2026, (USD Million)
Chapter 5 Global Monoclonal Antibodies Market, by End-User
5.1. Market Overview, by End-User
5.1.1. Global Monoclonal Antibodies Market, by End-User, 2016-2026 (USD Million)
5.1.2. Incremental Opportunity, by End-User, 2018
5.2. Hospitals
5.2.1. Global Monoclonal Antibodies Market, by Hospitals, 2016-2026, (USD Million)
5.3. Research Institutes
5.3.1. Global Monoclonal Antibodies Market, by Research Institutes, 2016-2026, (USD Million)
5.4. Others
5.4.1. Global Monoclonal Antibodies Market, by Others, 2016-2026, (USD Million)
Chapter 6 Global Monoclonal Antibodies Market, by Region
6.1. Market Overview, by Region
6.1.1. Global Monoclonal Antibodies Market, by Region, 2016-2026, (USD Million)
6.2. Attractive Investment Opportunity, by Region, 2018
6.3. North America Monoclonal Antibodies Market
6.3.1. North America Monoclonal Antibodies Market, by Type, 2016-2026 (USD Million)
6.3.2. North America Monoclonal Antibodies Market, by Indication, 2016-2026 (USD Million)
6.3.3. North America Monoclonal Antibodies Market, by End-User, 2016-2026 (USD Million)
6.3.4. United States Monoclonal Antibodies Market, 2016-2026 (USD Million)
6.3.5. Canada Monoclonal Antibodies Market, 2016-2026 (USD Million)
6.4. Europe Monoclonal Antibodies Market
6.4.1. Europe Monoclonal Antibodies Market, by Type, 2016-2026 (USD Million)
6.4.2. Europe Monoclonal Antibodies Market, by Indication, 2016-2026 (USD Million)
6.4.3. Europe Monoclonal Antibodies Market, by End-User, 2016-2026 (USD Million)
6.4.4. United Kingdom Monoclonal Antibodies Market, 2016-2026 (USD Million)
6.4.5. Germany Monoclonal Antibodies Market, 2016-2026 (USD Million)
6.4.6. France Monoclonal Antibodies Market, 2016-2026 (USD Million)
6.4.7. Rest of Europe Monoclonal Antibodies Market, 2016-2026 (USD Million)
6.5. Asia Pacific Monoclonal Antibodies Market
6.5.1. Asia Pacific Monoclonal Antibodies Market, by Type, 2016-2026 (USD Million)
6.5.2. Asia Pacific Monoclonal Antibodies Market, by Indication, 2016-2026 (USD Million)
6.5.3. Asia Pacific Monoclonal Antibodies Market, by End-User, 2016-2026 (USD Million)
6.5.4. China Monoclonal Antibodies Market, 2016-2026 (USD Million)
6.5.5. Japan Monoclonal Antibodies Market, 2016-2026 (USD Million)
6.5.6. India Monoclonal Antibodies Market, 2016-2026 (USD Million)
6.5.7. Rest of Asia Pacific Monoclonal Antibodies Market, 2016-2026 (USD Million)
6.6. Latin America Monoclonal Antibodies Market
6.6.1. Latin America Monoclonal Antibodies Market, by Type, 2016-2026 (USD Million)
6.6.2. Latin America Monoclonal Antibodies Market, by Indication, 2016-2026 (USD Million)
6.6.3. Latin America Monoclonal Antibodies Market, by End-User, 2016-2026 (USD Million)
6.6.4. Brazil Monoclonal Antibodies Market, 2016-2026 (USD Million)
6.6.5. Mexico Monoclonal Antibodies Market, 2016-2026 (USD Million)
6.6.6. Rest of Latin America Monoclonal Antibodies Market, 2016-2026 (USD Million)
6.7. Middle East & Africa Monoclonal Antibodies Market
6.7.1. Middle East & Africa Monoclonal Antibodies Market, by Type, 2016-2026 (USD Million)
6.7.2. Middle East & Africa Monoclonal Antibodies Market, by Indication, 2016-2026 (USD Million)
6.7.3. Middle East & Africa Monoclonal Antibodies Market, by End-User, 2016-2026 (USD Million)
6.7.4. GCC Monoclonal Antibodies Market, 2016-2026 (USD Million)
6.7.5. Rest of Middle East & Africa Monoclonal Antibodies Market, 2016-2026 (USD Million)
Chapter 7 Competitive Intelligence
7.1. Top 5 Players Comparison
7.2. Market Positioning of Key Players, 2018
7.3. Market Players Mapping
7.3.1. By Type
7.3.2. By Indication
7.3.3. By End-User
7.3.4. By Region
7.4. Strategies Adopted by Key Market Players
7.5. Recent Developments in the Market
7.5.1. Mergers & Acquisitions, Partnership, New Product Developments
Chapter 8 Company Profiles
8.1. Novartis International AG
8.1.1. Novartis International AG Overview
8.1.2. Novartis International AG Products Portfolio
8.1.3. Novartis International AG Financial Overview
8.1.4. Novartis International AG News/Recent Developments
8.2. Pfizer Inc.
8.2.1. Pfizer Inc. Overview
8.2.2. Pfizer Inc. Products Portfolio
8.2.3. Pfizer Inc. Financial Overview
8.2.4. Pfizer Inc. News/Recent Developments
8.3. GlaxoSmithKline plc
8.3.1. GlaxoSmithKline plc Overview
8.3.2. GlaxoSmithKline plc Products Portfolio
8.3.3. GlaxoSmithKline plc Financial Overview
8.3.4. GlaxoSmithKline plc News/Recent Developments
8.4. Amgen Inc.
8.4.1. Amgen Inc. Overview
8.4.2. Amgen Inc. Products Portfolio
8.4.3. Amgen Inc. Financial Overview
8.4.4. Amgen Inc. News/Recent Developments
8.5. Merck & Co., Inc.
8.5.1. Merck & Co., Inc. Overview
8.5.2. Merck & Co., Inc. Products Portfolio
8.5.3. Merck & Co., Inc. Financial Overview
8.5.4. Merck & Co., Inc. News/Recent Developments
8.6. Daiichi Sankyo, Inc.
8.6.1. Daiichi Sankyo, Inc. Overview
8.6.2. Daiichi Sankyo, Inc. Products Portfolio
8.6.3. Daiichi Sankyo, Inc. Financial Overview
8.6.4. Daiichi Sankyo, Inc. News/Recent Developments
8.7. Abbott Laboratories
8.7.1. Abbott Laboratories Overview
8.7.2. Abbott Laboratories Products Portfolio
8.7.3. Abbott Laboratories Financial Overview
8.7.4. Abbott Laboratories News/Recent Developments
8.8. AstraZeneca
8.8.1. AstraZeneca Overview
8.8.2. AstraZeneca Products Portfolio
8.8.3. AstraZeneca Financial Overview
8.8.4. AstraZeneca News/Recent Developments
8.9. Eli Lilly and Company
8.9.1. Eli Lilly and Company Overview
8.9.2. Eli Lilly and Company Products Portfolio
8.9.3. Eli Lilly and Company Financial Overview
8.9.4. Eli Lilly and Company News/Recent Developments
8.10. Johnson & Johnson
8.10.1. Johnson & Johnson Overview
8.10.2. Johnson & Johnson Products Portfolio
8.10.3. Johnson & Johnson Financial Overview
8.10.4. Johnson & Johnson News/Recent Developments
Chapter 9 Preface
9.1. Data Triangulation
9.2. Research Methodology
9.2.1. Indication I – Secondary Research
9.2.2. Indication II – Primary Research
9.2.3. Indication III – Expert Panel Review
9.2.4. Approach Adopted
9.2.4.1. Top-Down Approach
9.2.4.2. Bottom-Up Approach
9.2.5. Supply- Demand side
9.2.6. Breakup of the Primary Profiles
Log in / Register
